Concerns on Perrigo overdone, says RBC Capital RBC Capital reported that investors have become concerned about Perrigo due to a later start to the flu season, early mixed channel commentary and a lack of P&L clarity. But the firm thinks the concerns are overdone, as it believes that flu has less of an impact on Perrigo's business now than in the past, while the company has several unrelated upcoming positive catalysts. The firm keeps a Top Pick rating on the stock.
Perrigo would be good acquisition for Teva, says RBC Capital RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.